Fenofibrate Increases Homocystinemia through a PPARα-Mediated Mechanism

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 3, 2004, Pages 452-453

  Luc, Gérald ^a,b   Jacob, Nelly ^c   Bouly, Muriel ^a,b   Fruchart, Jean Charles ^a,b   Staels, Bart ^a,b   Giral, Philippe ^c  

^a INSTITUT PASTEUR DE LILLE   (France)

^b UNIV LILLE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Fibrate; Homocysteine; PPAR

Indexed keywords

CELL NUCLEUS RECEPTOR; FENOFIBRATE; HOMOCYSTEINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSCRIPTION FACTOR;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; GENE EXPRESSION; HOMOCYSTINURIA; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY;

ANIMALS; ANTILIPEMIC AGENTS; HOMOCYSTEINE; MICE; MICE, INBRED C57BL; PROCETOFEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 1442301511     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200403000-00017     Document Type: Article

References (11)

1. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999;10: 245-257.
2. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
3. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw Hill; 1989: 693-734.
4. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999;354:219-220.
5. Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet. 2001;358:39-40.
6. de Lorgeril M, Salen P, Paillard F, et al. Lipid-lowering drugs and homocysteine. Lancet. 1999;353:209-210.
7. Giral P, Bruckert E, Jacob N, et al. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis. 2001;154:421-427.
8. Schaefer EJ, Mcnamara JR, Selhub J, et al. Gemfibrozil treatment raised homocysteine concentrations in VA-HIT. Circulation. 2000;102:II847.
9. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator- activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995; 15:3012-3022.
10. Jacob N, Bruckert E, Giral P, et al. Cysteine is a cardiovascular risk factor in hyperlipidemic patients. Atherosclerosis. 1999;146:53-59.
11. Hottelart C, el Esper N, Achard JM, et al. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie. 1999;20:41-44.